ArticleFrontiers in medicine2026
Out"FOX"ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The forkhead box family transcription factor FOXC2 is an important oncogenic driver of several hallmarks of cancer progression. In addition to its well-characterized roles in tumor angiogenesis, metabolic adaptation, and the epithelial-mesenchymal transition that precedes invasion and metastasis, FOXC2 has recently been implicated in tumor immune evasion as well. This Perspective article highlights recent findings concerning the potential value of FOXC2 as a predictive biomarker for cancer immunotherapy and brings attention to data connecting FOXC2 dysregulation to critical determinants of anti-tumor immune outcome, including influences on the makeup of the tumor immune microenvironment and cancer cell responsiveness to type I and type II interferons. In summarizing the current state of knowledge surrounding the immunologic impact of FOXC2 dysregulation in cancer, this article also raises several important questions that will need to be addressed going forward as the field aims to better understand FOXC2's role in tumor immune evasion so that these insights may be leveraged into translatable interventions that enhance the efficacy of cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.